ARTICLE | Company News
Genomic Health launches colon cancer test
January 22, 2010 1:25 AM UTC
Genomic Health Inc. (NASDAQ:GHDX) launched its Oncotype DX colon cancer test worldwide to predict individual recurrence risk in stage II colon cancer patients following surgery. The price is $3,200 pe...